![Tome](https://www.longwoodfund.com/wp-content/uploads/2023/12/Tome-logo.png)
Tome Biosciences, Inc., is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies.